Mylan Inc.
NASDAQ: MYL
$15.86
+$0.00 (+0.0%)
Closing Price on November 19, 2020
MYL Articles
In a new report, UBS updates its list of quality growth at a reasonable price, or Q-GARP, stocks as they call them.
Published:
These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. on Monday, October 6, 2014.
Published:
Last Updated:
The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have created such a stir of late.
Published:
These are the top analyst upgrades and downgrades from 24/7 Wall St. for Wednesday, September 3, 2014.
Published:
Jon OggStocks turned green on Friday morning on hopes out of Russia, but the markets have remained at risk. Now that investors have an opportunity to look for stocks that have pulled back, 24/7 Wall...
Published:
These are this Friday's top analyst upgrades, downgrades and initiations from Wall Street firms on Friday, July 25, 2015. They include Amazon.com, Brightcove, Exxon, GM, Mylan, Petrobras and Twitter.
Published:
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include DuPont, General Electric, King, Microsoft, Xilinx and McDonald's.
Published:
Add one more to the litany of pharmaceutical company mergers that are being made to avoid U.S. taxes. Mylan's existing business with part of Abbott's generic drug business.
Published:
Last Updated:
Mylan reported first-quarter 2014 results before markets opened Thursday. The generic drug maker reaffirmed its full-year EPS guidance and hinted at an acquisition by the end of the year.
Published:
Shares of Mylan retreated first thing Monday morning, after the generic drugmaker's sweetened bid for Swedish drugmaker Meda was rejected.
Published:
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of the year.
Published:
In a new report, RBC has a list of stocks with some of the largest percentage drops and the lowest forward price-to-earnings (P/E) ratios. This may serve as shopping list for the second half of the...
Published:
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
Published:
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone...
Published:
Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be confirmation that Teva Pharmaceutical Industries is finally rebounding. Analysts think the stock...
Published: